Long-acting typical and atypical antipsychotics in treatment of schizophrenia: A retrospective comparison

Klinik Psikofarmakoloji Bulteni

Volumn 19, Issue 2, 2009, Pages 119-127

  Virit, Osman ^a   Altindag, Abdurrahman ^a   Bulbul, Feridun ^b   Savas, Haluk Asuman ^a   Dalkilic, Alican ^c,d  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b Department of Urology   (Turkey)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d St Elizabeths Hospital   (United States)

Author keywords

Depot antipsychotic; Long acting risperidone; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; RISPERIDONE; ZUCLOPENTHIXOL DECANOATE;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT COMPLIANCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 67649639327     PISSN: 10177833     EISSN: 13029657     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651. (Pubitemid 27485972)
2. West JC, Wilk JE, Olfson M, Rae DS, Marcus S, Narrow WE, Pincus HA, Regier DA. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005;283-291. (Pubitemid 40333560)
3. Robinson DG, Woerner MG, Alvir JM, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, Lieberman JA. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247. (Pubitemid 29125132)
4. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811. (Pubitemid 32577440)
5. Weiden P, Zygmunt A. Medication noncompliance in schizophrenia. J Pract Psychiatry Behav Health 1997;3:106-110.
6. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003;160:1125-1132. (Pubitemid 41070972)
7. Dencker SJ. The risk/benefit ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry 1984;45:22-27. (Pubitemid 14116750)
8. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Şeischhacker WW, Gaebel W, Gerlach J, Guelfi JD, Kissling W, Lapierre YD, Lindström E, Mendlewicz J, Racagni G, Carulla LS, Schooler NR. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55-66. (Pubitemid 28012861)
9. Kane JM. Pharmacologic treatment of schizophrenia. Biol Psychiatry 1999;46:1396-1408.
10. Glazer WM, Kane JM. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992;53:426-433. (Pubitemid 23018085)
11. Rothbard AB, Kuno E, Roley K. Trends in the rate and type of antipsychotic medications prescribe to persons with schizophrenia. Schizophr Bull 2003;29:531-540. (Pubitemid 37339387)
12. Babiker IE. Comparative efficacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry 1987;48:94-97. (Pubitemid 17047796)
13. Davis JM, Matalon L, Watanabe MD, Blake L. Depot antipsychotic drugs: place in therapy. Drugs 1994;47:741-773. (Pubitemid 24151095)
14. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2006.Available at:http://www.psych.org/psych pract/treatg.
15. Lehman AF, Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Goldberg R, Green-Paden LD, Tenhula WN, Boerescu D, Tek C, Sandson N, Steinwachs DM. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30: 193-217.
16. Kane JM, Leucht S, Carpenter D, Docherty JP. The Expert Consensus Guideline Series: optimizing pharmacologic treatment of psychotic disorders. J Clin Psychiatry 2003;64 (Suppl 12):5-19.
17. Citrome L, Levine J, Allingham B. Utilization of depot neuroleptic medication in psychiatric inpatients. Psychopharm Bull 1996;32:321-326. (Pubitemid 26365643)
18. Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR. Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. Psychiatr Serv 2007;58:482-488. (Pubitemid 46640638)
19. Arnold LM, Strakowski SM, Schwiers ML, Amicone J, Fleck DE, Corey KB, Farrow JE. Sex, ethnicity, and antipsychotic medication use in patients with psychosis. Schizophr Res 2004;66:169-175. (Pubitemid 38041116)
20. Walburn J, Gray R, Gournay K, Quarishi S, David AS. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300-307. (Pubitemid 32996038)
21. Markowitz JS, Brown CS, Moore TR. Atypical antipsychotics. Part I: pharmacology, pharmacokinetics, and efficacy. Ann Pharmacother 1999;33:73-85.
22. Masand PS, Berry SL. Switching antipsychotic therapies. Ann Pharmacother 2000; 34:200-207. (Pubitemid 30082979)
23. Csernansky JG, Mahmoud R, Brenner RA. Comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Eng J Med 2002;346:16-22. (Pubitemid 34438915)
24. Brown CS, Markowitz JS, Moore TR. Atypical antipsychotics. Part II: adverse effects, drug interactions, and costs. Ann Pharmacother 1999;33:210-217.
25. National Institute for Clinical Excellence Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Appraisal Guidance-No. 43. 2002. London: National Institute for Clinical Excellence.
26. Kirov GK, Murray RM, Seth RV, Feeney S. Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;. 95:439-443. (Pubitemid 27244845)
27. Desai NM, Huq Z, Martin SD, McDonald G. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. Adv Ther 1999;16:78-88. (Pubitemid 29244958)
28. Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C.Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006;51:531-539. (Pubitemid 44166341)
29. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004 ;19:219-225 (Pubitemid 38766136)
30. Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241-249. (Pubitemid 38901653)
31. Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Pharmacopsychiatry 2007; 40:257-263. (Pubitemid 350232817)
32. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007;33:1379-1387. (Pubitemid 350022772)
33. Kay SR, Fiszbein PS, Opler LA The positive and negative syndrome scale (PANNS) for schizophrenia. Schizophr Bull 1987;13:261-276. (Pubitemid 18039085)
34. Guy W. Clinical Global Impressions ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ. No. ADM 76- 338). (1976). National Institute of Mental Health: Rockville, MD. pp 218-222.
35. Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-639.
36. Keks NA, Altson K, Hope J, Krapivensky N, Culhane C, Tanaghow A, Doherty P, Bootle A. Use of antipsychosis and adjunctive medications by an inner urban community psychiatric service. Aust N Z J Psychiatry 1999;33:896-901. (Pubitemid 30015857)
37. Lacro JP, Dunn LB, Dolder CR, Leckban SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909. (Pubitemid 35231730)
38. Yildiz M, Yüksel AG. Why depot antipsychotic drug use in the treatment of psychotic disorders is still important? An investigation regarding clinical outcome. Klinik Psikofarmakoloji Bulteni 2006; 16:98-103 (Pubitemid 44047710)
39. Yumru M, Savaş HA, Kokaçya MH, Virit O. Long acting risperidone in treatment of schizophrenia: a retrospective study. Klinik Psikofarmakoloji Bulteni 2007; 17:119-123 (Pubitemid 47437405)
40. Wistedt B, Koskinen T, Thelander S, Nerdrum T, Pedersen V, Mlbjerg C. Zuclopenthixol decanoate and haloperidol decanoate in chronic schizophrenia: a double-blind multicentre study. Acta Psychiatr Scand. 1991;84:13-21.
41. Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia: a long-term double-blind cross-over comparison. Acta Psychiatr Scand. 1986;74:255-262. (Pubitemid 17175353)
42. Kane JM, Davis JM, Schooler N, Marder S, Casey D, Brauzer B, Mintz J, Conley R. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002;159:554-560. (Pubitemid 34274936)
43. Taylor DM, Young CL, Mace S, Patel MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004;65:1076-1083.
44. Walkup JT, McAlpine DD, Olfson M, Labay LE, Boyer C, Hansell S. Patients with schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000;61:344-348. (Pubitemid 30345935)
45. Price N, Glazer W, Morgenstern H. Demographic predictors of the use of injectable versus oral antipsychotic medications in outpatients. Am J Psychiatry 1985;142:1491-1492. (Pubitemid 16169894)
46. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62:545-551. (Pubitemid 32703095)
47. Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, Edgell ET, Ratcliffe M; SOHO Advisory Board. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:972-982. (Pubitemid 41080120)
48. Whitehead C, Moss S, Cardino A, Lewis G. Antidepressant for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002;2: CD002305.
49. Leucht S, McGrath J, White P, Kissling W. Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2007;3: CD001258.
50. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone inpatients with an acute exacerbation of schizophrenia. Neuropsychopharmacology 2003;28:182-192. (Pubitemid 37412115)
51. Fattinger K, Roos M, Vergëres P, Holenstein C, Kind B, Masche U, Stocker DN, Braunschweig S, Kullak-Ublick GA, Galeazzi RL, Follath F, Gasser T, Meier PJ. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000;49: 158-167. (Pubitemid 30068294)
52. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N E J Med 2005;353:1209-1223.
53. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a doubleblind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005;66:1016-1020. (Pubitemid 41191794)